ProfileGDS5678 / 1434908_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 75% 76% 74% 75% 77% 78% 76% 75% 75% 76% 75% 78% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.101176
GSM967853U87-EV human glioblastoma xenograft - Control 25.0582375
GSM967854U87-EV human glioblastoma xenograft - Control 35.1510776
GSM967855U87-EV human glioblastoma xenograft - Control 44.9340474
GSM967856U87-EV human glioblastoma xenograft - Control 54.9843775
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.1521277
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2195278
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.031676
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0183675
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.0489475
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.0493276
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.0020275
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.3146378
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.0510976